Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
about
'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic ReviewImpact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.Reference bias: presentation of extreme health states prior to EQ-VAS improves health-related quality of life scores. a randomised cross-over trial.Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab.Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment.Monoclonal antibodies and Fc fragments for treating solid tumors.Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic AnalysisClinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance studyElectrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis.Targeted therapies in colorectal cancer-an integrative view by PPPMBenefits, issues, and recommendations for personalized medicine in oncology in CanadaBiomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.Is overall survival still the primary endpoint in maintenance non-small cell lung cancer studies? An analysis of phase III randomised trials.MABp1 for the treatment of colorectal cancer.How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cellsCorrelation of progression-free and post-progression survival with overall survival in advanced colorectal cancer.Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma.Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis
P2860
Q31125157-22BFD9A7-0EEF-433B-9B5C-D6094FC1D1FCQ34000605-658BCCFE-904B-4FF7-97D6-AF042C74BDA0Q34439059-6F54F60F-1CEE-4215-81EA-328AAFF7837EQ34461509-75DE189B-CEA3-4EAB-A758-519693738452Q34508065-51AE792E-E401-4DF3-B26A-B0CC31E6A198Q35623078-43C34E1C-066F-48D3-9A89-497CE2F4069AQ35699372-87AAA4D8-9C38-4F55-9730-EEDD4EC2EDEAQ35913241-E0F2AAC4-9E2D-4F77-9112-A1DAEB43B826Q36039967-FEDA62FE-B4CA-47E2-AF02-FB6083EA5F8DQ36337416-75149FA1-7837-40A7-A96A-A33BA781B3DEQ36391779-8C41A319-DE8E-4065-A469-BBE2E6D77AA8Q36646911-6A692654-EF30-4E09-8383-9F4376543727Q37248023-9E4BF4AF-263E-48A6-993D-A413F3E99BCFQ37378581-E9DA09E5-2FBF-498D-B334-DB2637BAE672Q37615896-942EFB18-11B4-43B4-BBF5-01597D51E4BBQ38390009-4979EE2D-D629-4F9C-9D2E-F24A1F71701AQ38686881-54ECA2A2-C1A1-4504-B8F8-7E51AA36B740Q38826639-B6D8D0A2-1AD5-4FFB-8650-105A91334D55Q39315869-A2EF3F04-74DE-4386-865C-616C4F78FC97Q44365458-27731E0C-867D-430F-8FC1-21D429C78334Q44740561-D160C386-5DE2-466D-8292-92C47622BF08Q48462602-085DCCB3-A54C-48EB-9B4C-28C76493D745Q55003485-823D92D5-B7EF-4DA9-BCEC-C555C96188E7Q57494108-663EBC8F-2927-4FB2-8099-417AD52E939B
P2860
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Association of progression-fre ...... phase 3 trial of panitumumab.
@ast
Association of progression-fre ...... phase 3 trial of panitumumab.
@en
type
label
Association of progression-fre ...... phase 3 trial of panitumumab.
@ast
Association of progression-fre ...... phase 3 trial of panitumumab.
@en
prefLabel
Association of progression-fre ...... phase 3 trial of panitumumab.
@ast
Association of progression-fre ...... phase 3 trial of panitumumab.
@en
P2093
P2860
P50
P356
P1476
Association of progression-fre ...... d phase 3 trial of panitumumab
@en
P2093
D Comandini
E Van Cutsem
G Devercelli
G Van Hazel
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604053
P407
P577
2007-11-27T00:00:00Z